… , and welcome to the Protalix BioTherapeutics, Inc. Third Quarter … by the Committee of Medicinal Products for Human Use … treatment of uncontrolled gout. Preparation for the phase two clinical trial … become effective following the FDA’s standard thirty-day …

… behalf of investors of Protalix BioTherapeutics, Inc. (“Protalix” or “the Company … pertinent to investors. Protalix and Chiesi Global Rare … that the Committee for Medicinal Products for Human Use … (CHMP) of the European Medicines Agency (EMA) has issued …

… immediately and initiate appropriate medical treatment. In patients with … FDA and the European Medicines Agency in May 2023. Protalix … that target established pharmaceutical markets, including the … trials; the inherent risks and uncertainties in developing drug …

… immediately and initiate appropriate medical treatment. In patients with … FDA and the European Medicines Agency in May 2023. Protalix … that target established pharmaceutical markets, including the … trials; the inherent risks and uncertainties in developing drug …

… European Medicines Agency (EMA) has issued a negative opinion for Protalix BioTherapeutics … on data from the BRIGHT trial (formally PB-102-F50) … exposure-response analyses across prior trials (PB-102-F01/- … its Phase 1/2a trial of AMT-191, an …

… to reduce treatment burden for patients with Fabry disease. Protalix BioTherapeutics … that the Committee for Medicinal Products for Human Use … (CHMP) of the European Medicines Agency (EMA) has issued … the company to reduce treatment burden for patients with …

… trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA … medications and lifestyle modifications. Find out more about gout drugs @ Gout Treatment … Pharmaceutical LLC, Hikma Pharmaceuticals plc, Takeda Pharmaceutical …

… s Disease Clinical Trials The treatment landscape for Gaucher … China's biotech sector as the … secured US FDA Investigational New Drug (IND) approval … Lingyimed, Takeda Pharmaceuticals, Pfizer, Protalix BioTherapeutics, Actelion Pharmaceuticals, now part …

… making substantial investments in medical, regulatory and successful … enhance patients’ compliance and treatment flexibility. As we … our Protalix platform and PEGylation capabilities, evaluating drug delivery … preclinical and clinical trials for certain of …

… .S. Food and Drug Administration (FDA) approval of a … FDA and the European Medicines Agency in May 2023. Protalix … proteins that target established pharmaceutical markets, including the following … PEGylated uricase for the treatment of uncontrolled gout; PRX …